Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4514-4520.DOI: 10.12114/j.issn.1007-9572.2023.0095
Special Issue: 肿瘤最新文章合集; 消化系统疾病最新文章合集
• Article • Previous Articles Next Articles
Received:
2023-01-15
Revised:
2023-06-20
Published:
2023-12-20
Online:
2023-07-19
Contact:
ZHU Hong
通讯作者:
朱红
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0095
指标 | 计算公式 |
---|---|
APRI | (AST/ASTULN)×100/PLT |
FIB-4 | (年龄×AST)/PLT×(ALT1/2) |
GPR | GGT/GGTULN×100/PLT |
S-Index | 1 000×GGT/(PLT×ALB2) |
NLR | NE/LY |
PLR | PLT/LY |
FAR | FIB/ALB |
LMR | LY/MO |
NrLR | NE×GGT/LY |
SIRI | MO×NE/LY |
SII | PLT×NE/LY |
PNI | ALB+5×LY |
ALRI | AST/LY |
AAR | AST/ALT |
ANRI | AST/NE |
Table 1 Formulas for the calculation of 15 serologically derived indicators
指标 | 计算公式 |
---|---|
APRI | (AST/ASTULN)×100/PLT |
FIB-4 | (年龄×AST)/PLT×(ALT1/2) |
GPR | GGT/GGTULN×100/PLT |
S-Index | 1 000×GGT/(PLT×ALB2) |
NLR | NE/LY |
PLR | PLT/LY |
FAR | FIB/ALB |
LMR | LY/MO |
NrLR | NE×GGT/LY |
SIRI | MO×NE/LY |
SII | PLT×NE/LY |
PNI | ALB+5×LY |
ALRI | AST/LY |
AAR | AST/ALT |
ANRI | AST/NE |
组别 | 例数 | 性别(男/女) | 年龄≥60岁〔例(%)〕 | 乙肝病史〔例(%)〕 | 肝硬化〔例(%)〕 | AFP>45 ng/mL 〔例(%)〕 | TB>20.5 μmol/L 〔例(%)〕 | ALB<35 g/L 〔例(%)〕 | ALT>40 U/L 〔例(%)〕 | AST>40 U/L 〔例(%)〕 | ALP>125 U/L 〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|---|---|
MVI阳性 | 108 | 94/14 | 30(27.8) | 94(87.0) | 68(63.0) | 68(63.0) | 29(26.7) | 94(87.0) | 60(55.6) | 67(62.0) | 48(44.4) |
MVI阴性 | 100 | 81/19 | 31(31.0) | 88(88.0) | 71(71.0) | 43(43.0) | 28(28.0) | 86(86.0) | 52(52.0) | 56(56.0) | 30(30.0) |
χ2值 | 1.418 | 0.26 | 0.044 | 1.513 | 8.315 | 0.034 | 0.048 | 0.264 | 0.783 | 4.622 | |
P值 | 0.234 | 0.610 | 0.834 | 0.219 | 0.004 | 0.853 | 0.827 | 0.607 | 0.376 | 0.032 | |
组别 | GGT>50 U/L 〔例(%)〕 | INR>1.185 〔例(%)〕 | PT延长〔例(%)〕 | FIB>3.03 g/L 〔例(%)〕 | WBC> 7.1×109/L 〔例(%)〕 | NE>4.735 ×109/L 〔例(%)〕 | MO>0.545 ×109/L 〔例(%)〕 | PLT> 155.5×109/L 〔例(%)〕 | 肿瘤直径>7.05 cm 〔例(%)〕 | 肿瘤数目>1个〔例(%)〕 | |
MVI阳性 | 82(76.0) | 17(15.7) | 10(9.3) | 67(62.0) | 37(34.2) | 30(27.8) | 30(27.8) | 66(61.1) | 54(50.0) | 34(31.5) | |
MVI阴性 | 69(69.0) | 12(12.0) | 6(6.0) | 50(50.0) | 17(17.0) | 11(11.0) | 17(17.0) | 46(46.0) | 15(15.0) | 16(16.0) | |
χ2值 | 1.252 | 0.606 | 0.777 | 3.057 | 8.047 | 9.235 | 3.448 | 4.771 | 28.692 | 6.815 | |
P值 | 0.263 | 0.436 | 0.378 | 0.080 | 0.005 | 0.002 | 0.063 | 0.029 | <0.001 | 0.009 |
Table 2 Comparison of baseline characteristics of MVI-positive and MVI-negative patients in the model group
组别 | 例数 | 性别(男/女) | 年龄≥60岁〔例(%)〕 | 乙肝病史〔例(%)〕 | 肝硬化〔例(%)〕 | AFP>45 ng/mL 〔例(%)〕 | TB>20.5 μmol/L 〔例(%)〕 | ALB<35 g/L 〔例(%)〕 | ALT>40 U/L 〔例(%)〕 | AST>40 U/L 〔例(%)〕 | ALP>125 U/L 〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|---|---|
MVI阳性 | 108 | 94/14 | 30(27.8) | 94(87.0) | 68(63.0) | 68(63.0) | 29(26.7) | 94(87.0) | 60(55.6) | 67(62.0) | 48(44.4) |
MVI阴性 | 100 | 81/19 | 31(31.0) | 88(88.0) | 71(71.0) | 43(43.0) | 28(28.0) | 86(86.0) | 52(52.0) | 56(56.0) | 30(30.0) |
χ2值 | 1.418 | 0.26 | 0.044 | 1.513 | 8.315 | 0.034 | 0.048 | 0.264 | 0.783 | 4.622 | |
P值 | 0.234 | 0.610 | 0.834 | 0.219 | 0.004 | 0.853 | 0.827 | 0.607 | 0.376 | 0.032 | |
组别 | GGT>50 U/L 〔例(%)〕 | INR>1.185 〔例(%)〕 | PT延长〔例(%)〕 | FIB>3.03 g/L 〔例(%)〕 | WBC> 7.1×109/L 〔例(%)〕 | NE>4.735 ×109/L 〔例(%)〕 | MO>0.545 ×109/L 〔例(%)〕 | PLT> 155.5×109/L 〔例(%)〕 | 肿瘤直径>7.05 cm 〔例(%)〕 | 肿瘤数目>1个〔例(%)〕 | |
MVI阳性 | 82(76.0) | 17(15.7) | 10(9.3) | 67(62.0) | 37(34.2) | 30(27.8) | 30(27.8) | 66(61.1) | 54(50.0) | 34(31.5) | |
MVI阴性 | 69(69.0) | 12(12.0) | 6(6.0) | 50(50.0) | 17(17.0) | 11(11.0) | 17(17.0) | 46(46.0) | 15(15.0) | 16(16.0) | |
χ2值 | 1.252 | 0.606 | 0.777 | 3.057 | 8.047 | 9.235 | 3.448 | 4.771 | 28.692 | 6.815 | |
P值 | 0.263 | 0.436 | 0.378 | 0.080 | 0.005 | 0.002 | 0.063 | 0.029 | <0.001 | 0.009 |
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
WBC>7.1×109/L | 1.146 | 0.450 | 6.475 | 3.144(1.301,7.598) | 0.011 |
肿瘤直径>7.05 cm | 1.344 | 0.398 | 11.399 | 3.836(1.758,8.372) | 0.001 |
S-Index>0.097 | 1.152 | 0.576 | 4.006 | 3.165(1.024,9.779) | 0.040 |
AAR>0.879 | 0.764 | 0.359 | 4.527 | 2.146(1.062,4.337) | 0.030 |
ANRI>24.074 | 1.018 | 0.437 | 5.422 | 2.769(1.175,6.526) | 0.020 |
Table 3 Multivariate Logistic regression analysis of MVI in patients with HCC
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
WBC>7.1×109/L | 1.146 | 0.450 | 6.475 | 3.144(1.301,7.598) | 0.011 |
肿瘤直径>7.05 cm | 1.344 | 0.398 | 11.399 | 3.836(1.758,8.372) | 0.001 |
S-Index>0.097 | 1.152 | 0.576 | 4.006 | 3.165(1.024,9.779) | 0.040 |
AAR>0.879 | 0.764 | 0.359 | 4.527 | 2.146(1.062,4.337) | 0.030 |
ANRI>24.074 | 1.018 | 0.437 | 5.422 | 2.769(1.175,6.526) | 0.020 |
指标 | 模型组 | 验证组 |
---|---|---|
一致性指数(95%CI) | 0.800(0.739,0.861) | 0.755(0.641,0.868) |
截断值(分) | 174 | 174 |
灵敏度(%) | 90 | 78 |
特异度(%) | 61 | 71 |
阳性预测值(%) | 71 | 76 |
阴性预测值(%) | 85 | 74 |
阳性似然比 | 2.30 | 2.73 |
阴性似然比 | 0.17 | 0.31 |
Table 4 Accuracy of prediction model in predicting MVI
指标 | 模型组 | 验证组 |
---|---|---|
一致性指数(95%CI) | 0.800(0.739,0.861) | 0.755(0.641,0.868) |
截断值(分) | 174 | 174 |
灵敏度(%) | 90 | 78 |
特异度(%) | 61 | 71 |
阳性预测值(%) | 71 | 76 |
阴性预测值(%) | 85 | 74 |
阳性似然比 | 2.30 | 2.73 |
阴性似然比 | 0.17 | 0.31 |
[1] |
|
[2] |
|
[3] |
蔡雪红,陈巍,陈世杰,等. 肝细胞癌术前预测微血管侵犯的研究进展[J]. 中南医学科学杂志,2022,50(3):462-465. DOI:10.15972/j.cnki.43-1509/r.2022.03.040.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
邓家仲,荚卫东. 肝细胞癌微血管侵犯危险因素分析及术前预测列线图模型构建[J]. 中国普通外科杂志,2021,30(7):772-779. DOI:10.7659/j.issn.1005-6947.2021.07.003.
|
[9] |
|
[10] |
|
[11] |
|
[12] |
姚岚清,陈钟. 原发性肝细胞肝癌微血管侵犯的术前预测及其模型的建立[J]. 中国肿瘤外科杂志,2021,13(1):5-11. DOI:10.3969/j.issn.1674-4136.2021.01.002.
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
王丽艳,孔凡刚. 肝病患者血清中AST/ALT比值的临床意义研究[J]. 中西医结合心血管病电子杂志,2020,8(30):97-98. DOI:10.16282/j.cnki.cn11-9336/r.2020.30.074.
|
[19] |
|
[20] |
|
[21] |
邹伟婕,陈立,黄学卿,等. 天冬氨酸转氨酶与中性粒细胞比值对肝癌患者TACE治疗预后的影响[J]. 介入放射学杂志,2017,26(8):705-711. DOI:10.3969/j.issn.1008-794X.2017.08.010.
|
[1] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[2] | WANG Shiyue, DONG Chen, CHANG Chudi, NAN Yuemin. Opportunities and Challenges of Surveillance for Liver Cancer in Primary Care Institutions in China [J]. Chinese General Practice, 2023, 26(36): 4498-4504. |
[3] | CHENG Hao, ZHOU Jinchi, LIU Xi, KANG Lin, FAN Ahui, DOU Weijia, LIU Zhenxiong. Risk Factors Analysis and Risk Prediction Model Establishment for Rebleeding Events within 3 Years after Endoscopic Treatment of Gastroesophageal Varices in Liver Cirrhosis Patients [J]. Chinese General Practice, 2023, 26(35): 4446-4452. |
[4] | LU Yihan, WANG Jiwen, SUN Yue, FENG Runrun, HAN Yufei, SONG Zhenzhen, SUN Ying, DAI Huihua, CHEN Xing. Risk Factors and Maternal and Neonatal Outcomes of Pregnant Women with Total Labor over 24 Hours [J]. Chinese General Practice, 2023, 26(35): 4459-4463. |
[5] | LIU Weina, GE Haiyan, MA Jing, CAO Qinying, BAI Xingyu, CUI Shifang, QIAO Yanxia. A Study on the Relationship of Vitamin A and E Levels in Umbilical Cord Blood with Respiratory Distress Syndrome in Preterm Infants [J]. Chinese General Practice, 2023, 26(33): 4152-4158. |
[6] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[7] | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou. Interpretation of Report on Cardiovascular Health and Diseases in China 2022 [J]. Chinese General Practice, 2023, 26(32): 3975-3994. |
[8] | LI Yujing, JIN Yichao, CHEN Xing, JI Mengying, DAI Huihua. Risk Factors for Endometrial Lesions Detected by Hysteroscopy in Breast Cancer Patients Taking Tamoxifen [J]. Chinese General Practice, 2023, 26(32): 4026-4030. |
[9] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
[10] | WANG Zhen, SHEN Guoqi, LI Yanan, ZHU Yinghua, QIU Hang, ZHENG Di, XU Tongda, LI Wenhua. Development and Validation of a Risk Prediction Model for Contrast-induced Acute Kidney Injury after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(29): 3650-3656. |
[11] | LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268. |
[12] | REN Yuanyuan, CHENG Gong, JIANG Hongying, WANG Yiyang, CHEN Liang, ZHAO Hui, LIANG Chenyuan. Analysis of Influencing Factors of Coronary Artery Calcification and Its Severity in Patients with Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(24): 2980-2985. |
[13] | HE Manlan, YUAN Ping, HE Lei, CHEN Lu. Meta-analysis of Risk Factors for Urinary Tract Infection in Neurogenic Bladder [J]. Chinese General Practice, 2023, 26(21): 2659-2665. |
[14] | FENG Shuidong, LI Junyan, DENG Shuxiang, CHEN Limou, CAO Mengyue, TANG Yan, TANG Peng, LIU Jun, SHEN Minxue, YANG Fei. Association between Air Pollutant Exposure and Dyslipidemia in Middle-aged and Elderly People in Mining Areas [J]. Chinese General Practice, 2023, 26(18): 2238-2244. |
[15] | XUE Jingru, SUN Suzhen. Clinical Characteristics and Risk Factors for Unfavourble Prognosis of Mycoplasma Pneumoniae Encephalitis in Children [J]. Chinese General Practice, 2023, 26(17): 2125-2131. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||